Navigation Links
Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer
Date:7/10/2008

tential equity investors, reliance on key strategic alliances, capital markets, and in general risks related to the regulatory environment and government approval processes, and any other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under applicable law.


'/>"/>
SOURCE Synovics Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals
2. Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC
3. Synovics Pharmaceuticals Announces Execution of Hormonal Manufacture and Supply Contract
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 The V Foundation for ... funding organizations, is excited to announce numerous promotions taking ... and many long-standing partnerships highlight The V Foundation’s significant ... expanding ways for all to get involved. Awarding ... cancer research, The V Foundation has funded more than ...
(Date:2/27/2015)... February 27, 2015 The federal court ... that allege use of the statin medication can increase ... issued a new order pertaining discovery in the cases ... Liebhard LLP comments. The Order, which was issued in ... February 25th, directs the parties to schedule certain witness ...
(Date:2/27/2015)... 27, 2015 Royal River Natural Foods, a ... new study that found adults who got the most magnesium ... diabetes compared to those who got the least magnesium, with ... , The report is part of the March 2015 issue ... River Natural Foods publishes free each month for the Freeport ...
(Date:2/27/2015)... Dr. Andrew Campbell, one of the ... to announce the expansion of Quintessa Aesthetic Center with ... has begun seeing patients on February 18, 2015. , ... offer a variety of state-of-the-art surgical and non-surgical ... laser peels, chemical peels, microdermabrasion, ProFractional Laser, Broad Band ...
(Date:2/27/2015)... According to court documents, Donna Pirolli was a ... and underwent a procedure during which a duodenoscope was ... the duodenoscope allegedly had not been properly cleaned, Donna ... (CRE). , A lawsuit has been proceeding ... of Ms. Pirolli alleging that Lutheran General Hospital was ...
Breaking Medicine News(10 mins):Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 3Health News:New Study Finds Magnesium May Slow Progress of Diabetes, Retailer Reports 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 3Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2
... at Wake Forest University School of Medicine reveals that many ... immediate medical needs of a student or employee who suffers ... to support a new statewide program to place automated external ... to appear in the May/June 2009 issue of the ...
... (SIS) unveils SIS Trax, a tissue management solution that ... for hospitals to standardize their processes for acquiring, receiving, ... solution to be fully integrated with a perioperative information ... enables hospitals to improve patient safety, optimize revenue, reduce ...
... Conference Vice President for Public Policy Paul A. ... executive order to be issued by President Obama ... cell research:"President Obama,s executive order regrettably places ideology ... advancements. There are endless studies and stories ...
... Connectivity to be Presented at HIMSS09LOS ANGELES, ... (OTC Bulletin Board: FVRL), which through its ... provides Web-based consumer-controlled Personal Health Records ("PHRs") ... box storage solutions ( www.myesafedepositbox.com ), announced ...
... Chef Cat Cora ( www.catcoracooks.com ), ... Chef of Bon Appetit is excited to announce she ... her first pregnancy and the fourth child for the Cora family. ... deliver their third child, also a boy, in April. "Jennifer and ...
... Seen in Patient Delays and Unnecessary StaysCOLLEGE PARK, Md., March ... Maryland,s Robert H. Smith School of Business put a ... hospitals at $12 billion per year. The research, newly released ... is the first to quantify the economic impact of a ...
Cached Medicine News:Health News:Study prompts new mandate for N.C. high schools 2Health News:Study prompts new mandate for N.C. high schools 3Health News:SIS Trax Unveiled as First Fully Integrated Tissue Management Solution 2Health News:MyMedicalRecords Adds Enhanced Doctor-Patient Features to Its Flagship Personal Health Record Platform 2Health News:MyMedicalRecords Adds Enhanced Doctor-Patient Features to Its Flagship Personal Health Record Platform 3Health News:MyMedicalRecords Adds Enhanced Doctor-Patient Features to Its Flagship Personal Health Record Platform 4Health News:Celebrity Chef Cat Cora Announces First Pregnancy 2Health News:U.S. Hospitals Waste $12 Billion Annually Because of Poor Communication 2Health News:U.S. Hospitals Waste $12 Billion Annually Because of Poor Communication 3
(Date:2/27/2015)... 27, 2015  Pomerantz LLP is investigating claims on ... the "Company") (NASDAQ: VTAE ).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... its officers and/or directors have violated Sections 10(b) and ... On February 27, 2015, the Company announced ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... a pre-clinical study published in the Proceedings ... www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib (IMBRUVICA ® ... checkpoint inhibitor), suppression of tumor growth was enhanced ... treating certain hematologic cancers and solid tumors with ...
(Date:2/27/2015)... 27, 2015  Acsis Inc., the market leader for ... today that John DiPalo , Acsis, Chief Strategy ... Demand Chain Executive 2015 Provider Pro to Know. ... initiatives to help prepare their companies, and customers, supply ... This year,s list of Provider Pros to Know is ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2
... (DSMB) Authorizes Enrollment of Cervical ... Authorized Dosage Level, HOPKINTON, Mass., Sept. 24 ... independent Data,Safety Monitoring Board (DSMB) has unanimously authorized expanding ... injury (SCI) to,allow subjects with cervical SCI to be ...
... Enrollment Ahead of Schedule with Completion Expected Q2 ... Inc. (Nasdaq: ALTH ) today announced the ... safety data from the,Company,s pivotal Phase 2 PROPEL ... refractory peripheral T-cell lymphoma (PTCL). Results of,the interim ...
Cached Medicine Technology:Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 2Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 3Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 4Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 5Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 2Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 3Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 4Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 5
... surgery and other types of refractive surgery. ... stromal bed. Flattened tip provides easy insertion ... flap edge. Multiple ports provide multi-directional irrigation. ... 7mm from end. Two .15mm ports 2mm, ...
... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. 21G x 7/8in (.80 ...
Cannula tip is specially rounded, extra smooth for safe insertion through wound and manipulation in the anterior chamber. 23G x 7/8 in (.60 x 22mm). .3mm end port. Olive shape tip is 2mm long x 1mm w...
For injecting anesthetics into the muscle cone. 25G x 1 1/2 in (.50 x 38mm)...
Medicine Products: